Onconova 04-30 (R/R)

Onconova 04-30 (R/R)

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome (MDS) After Failure of a Hypomethylating Agent (HMA)


Study treatments

Experimental arm
Intravenous Rigosertib 1800 mg/24h on days 1, 2 and 3 of a 2-week cycle for the first 8 cycles, and on days 1, 2 and 3 of a 4-week cycle thereafter
Active Comparator
Physician's Choice of Treatment - any approved or standard-of-care therapy


Inclusion criteria


Exclusion criteria


Participating sites


Link